CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 4, 2018--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming healthcare investor conferences.

Conference Details :

Event: Citi’s 13 th Annual Biotech Conference Date: Wednesday, September 5, 2018 Location: Boston, MA

Event: Morgan Stanley 16 th Annual Global Healthcare Conference Date/Time: Thursday, September 13, 2018 at 1:30 p.m. EDT Location: New York, NY

Event: Leerink Partners Roundtable Series: Rare Disease & Oncology Date/Time: Tuesday, October 2, 2018 at 9:30 a.m. EDT Location: New York, NY

A live webcast of the fireside chat at the Morgan Stanley and Leerink Partners conferences may be accessed on the Investors/Media page of the Company's website at  www.acceleronpharma.com. A replay of each webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit  www.acceleronpharma.com. Follow Acceleron on Social Media:  @AcceleronPharma  and  LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005257/en/

CONTACT: Acceleron Pharma Inc.

Todd James, IRC, 617-649-9393

Vice President, Investor Relations and Corporate Communications

or

Candice Ellis, 617-649-9226

Manager, Investor Relations and Corporate Communications

or

Media:

Matt Fearer, 617-301-9557

Director, Corporate Communications

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL GENERAL HEALTH

SOURCE: Acceleron Pharma

Copyright Business Wire 2018.

PUB: 09/04/2018 07:00 AM/DISC: 09/04/2018 07:01 AM

http://www.businesswire.com/news/home/20180904005257/en